TY - JOUR
T1 - Targets for medical therapy to limit abdominal aortic aneurysm progression
AU - Emeto, Theophilus I.
AU - Seto, Sai-Wang
AU - Golledge, Jonathan
PY - 2014
Y1 - 2014
N2 - Abdominal aortic aneurysm (AAA) is an important cause of mortality in older adults. Most AAAs are asymptomatic and screening programs have been introduced to identify AAAs at an early stage in some countries. There is currently no accepted therapy for early stage or small AAAs, which are frequently identified by such programs. In this review, we discuss work underway to identify targets for medical treatments to limit progression of small AAAs. Specifically we discuss studies, which have examined the potential of targeting inflammation, proteolysis, the renin-angiotensin system, the coagulation system and sex hormones as approaches to limiting AAA pathogenesis. As yet, none of the treatment targets have translated into an agent, which can effectively reduce AAA progression in clinical practice.
AB - Abdominal aortic aneurysm (AAA) is an important cause of mortality in older adults. Most AAAs are asymptomatic and screening programs have been introduced to identify AAAs at an early stage in some countries. There is currently no accepted therapy for early stage or small AAAs, which are frequently identified by such programs. In this review, we discuss work underway to identify targets for medical treatments to limit progression of small AAAs. Specifically we discuss studies, which have examined the potential of targeting inflammation, proteolysis, the renin-angiotensin system, the coagulation system and sex hormones as approaches to limiting AAA pathogenesis. As yet, none of the treatment targets have translated into an agent, which can effectively reduce AAA progression in clinical practice.
KW - abdominal aortic aneurysms
KW - aneurysms
KW - animal models
KW - pharmacotherapy
UR - http://handle.uws.edu.au:8081/1959.7/uws:29383
U2 - 10.2174/1389450115666140804155036
DO - 10.2174/1389450115666140804155036
M3 - Article
SN - 1389-4501
VL - 15
SP - 860
EP - 873
JO - Current Drug Targets
JF - Current Drug Targets
IS - 9
ER -